Standard care informed by the result of a placental growth factor blood test versus standard care alone in women with reduced fetal movement at or after 36⁺⁰ weeks' gestation: a pilot randomised controlled trial.

ABSTRACT:

Background

Biomarkers of placental function can potentially aid the diagnosis and prediction of pregnancy complications. This randomised controlled pilot trial assessed whether for women with reduced fetal movement (RFM), intervention directed by the measurement of a placental biomarker in addition to standard care was feasible and improved pregnancy outcome compared with standard care alone.

Methods

Women aged 16-50 years presenting at eight UK maternity units with RFM between 36⁺⁰ and 41⁺⁰ weeks' gestation with a viable singleton pregnancy and no indication for immediate delivery were eligible. Participants were randomised 1:1 in an unblinded manner to standard care and a biomarker blood test result revealed and acted on (intervention arm) or standard

SUBMITTER: Armstrong-Buisseret L 

PROVIDER: S-EPMC7020549 | biostudies-literature | 2020

REPOSITORIES: biostudies-literature